Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
D000911:Antibodies, Monoclonal; D001921:Brain / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000235:genetics* / Q000473:pathology; D002869:Chromosome Aberrations; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D005799:Genes, Dominant; D006801:Humans; D017403:In Situ Hybridization; D016518:Neurofibromatosis 2 / Q000235:genetics* / Q000473:pathology; D009464:Neuroma, Acoustic / Q000235:genetics* / Q000473:pathology; D010525:Peripheral Nerves / Q000473:pathology; D010524:Peripheral Nervous System Neoplasms / Q000235:genetics* / Q000473:pathology; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D013116:Spinal Cord / Q000473:pathology; D010959:Tissue Plasminogen Activator / Q000235:genetics*; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics*; D019096:Vitronectin / Q000235:genetics
D000911:Antibodies, Monoclonal; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D019096:Vitronectin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator